Until now, serologic tests that distinguish the closely related human T-cell lymphotropic virus types I (HTLV-I) and II (HTLV-II) infections have not been available. Synthetic peptide assays, employing peptides derived from the core and envelope proteins of HTLV-I and HTLV-II (SynthEIA and Select-HTLV tests), were evaluated for the ability to serologically discriminate HTLV-I and HTLV-II infections. Of 32 HTLV-I-and 57 HTLV-II-positive serum specimens from individuals whose infections were confirmed by polymerase chain reaction, the SynthEIA test categorized 29 (91%) as HTLV-I and 50 (88%) as HTLV-II, and 10 (11%) were nontypeable. In contrast, the Select-HTLV test categorized 32 (100%) as HTLV-I and 55 (96%) as HTLV-II, and 2 (2%) were nontypeable. The specificity of both the assays in seropositive serum specimens was 100% in that none of the specimens were incorrectly classified. Additional serum specimens obtained from clinically diseased patients from the United States (n = 8) and asymptomatic carriers and patients from Japan (an endemic population for HTLV-I; n = 40) were categorized as HTLV-I by at least one of the assays, while serum specimens from Guaymi Indians from Panama (an endemic population for HTLV-II; n = 13) were categorized as HTLV-II. Thus, peptide enzyme immunoassays appear to represent a simple technique employing chemically synthesized antigens for discrimination between antibodies of HTLV-I and HTLV-II.
Infection with human T-cell lymphotropic virus type-I (HTLV-I), the retrovirus etiologically associated with adult T-cell leukemia (ATL) and HTLV-I-associated myelopathy/ tropical spastic paraparesis (HAM/TSP), is endemic in areas such as southwestern Japan, the Caribbean, and some areas of sub-Saharan Africa (2, 25) . Although present to a lesser degree in the United States, seropositivity for HTLV-I (or to the closely related retrovirus HTLV-II) is reported for intravenous (i.v.) drug users (21, 24) , female prostitutes (12) , patients attending sexually transmitted disease clinics (13) , recipients of multiple blood transfusions (27) , and volunteer blood donors (1, 29) . Most seropositivity in the United States to HTLV type I or II (HTLV-I/II) in i.v. drug users and approximately half of that in volunteer blood donors is due to HTLV-II (3, 27) . This virus has also been found to be endemic in Guaymi Indians in Panama (9, 17) . In contrast to HTLV-I, HTLV-II is not known to be associated with any specific disease (11) .
Seroepidemiologic surveys, counseling of HTLV-I/II-seropositive blood donors, and studies on disease association of HTLV types I and II are complicated by an inability of currently available serologic assays to distinguish between HTLV-I and HTLV-II. Enzyme-linked immunoassays (EIAs) , in which whole virus lysates are used as the antigen source, cannot effectively distinguish HTLV-I from HTLV-II because of the similarity in structural proteins of these viruses (8) . Current methods that effectively differentiate between HTLV-I and HTLV-II are virus isolation and selective viral nucleic acid amplification based on polymerase chain reaction (PCR) analysis (15) . However, both of these techniques require lymphocytes from infected individuals and are technically complex, which limit their use in large-scale epidemiologic and clinical studies. Serologic tests that are simple, sensitive, and specific are therefore needed for detection of type-specific virus, particularly in locales where both viruses are endemic.
Synthetic peptides representing immunoreactive type-specific domains of viral proteins offer an alternate approach to design sensitive and specific immunoassays to distinguish between related retroviruses such as human immunodeficiency virus types 1 and 2 (6). Several structural motifs on both gag and env proteins of HTLV-I and HTLV-II have been defined by use of either synthetic peptides (10, 14, 19, 20, 23) or recombinant proteins (4, 5, 22, 26) . Some of these epitopes have been used to serologically discriminate HTLV-I from HTLV-II infections (20, 22) . We report here our results with two commercially available synthetic peptide-based immunoassays which are capable of serologically distinguishing between HTLV-I and HTLV-II infections.
MATERIALS AND METHODS
Human serum specimens. A total of 150 serum specimens from subjects who were seropositive for HTLV-I/II were tested (Table 1) . Of 89 serum specimens, 32 were categorized as HTLV-I and 57 were categorized as HTLV-II by PCR assays. Of the 32 HTLV-I-infected subjects, 8 19) , an area where HTLV-I infection is endemic, or Guaymi Indians from Panama (n = 13), a population in which HTLV-IT is endemic (9) .
Reference HTLV antibody tests. Patients' serum specimens were initially tested for HTLV-I antibodies with a commercial enzyme-linked immunosorbent assay (HTLV-1 ELISA; Dupont, Wilmington, Del.), according to the manufacturer's recommendations. Specimens that were repeatedly reactive were further tested by Western blotting (immunoblotting) and radioimmunoprecipitation assay as described previously (7) . Serum specimens that were HTLV-I/II-seropositive demonstrated antibody reactivity to gag p24 and env gp46 and/or gp68 by either Western blotting or radioimmunoprecipitation analysis. Serum specimens showing antibody reactivity to gag products only were considered indeterminate and were not included in this study. Recent studits have demonstrated very low prevalence (<3%) of HTLV infection in these seroindeterminate specimens (16) .
PCR assays. PCR analysis was performed with total genomic DNA isolated from patients' peripheral blood lymphocytes by using reaction conditions as described previously (15) . Oligonucleotide primer pairs (SK 110/111) from a consensus region of pol gene were used for amplification, which was followed by type-specific probing (SK112 for HTLV-I and SK188 for HTLV-II) (15) . Additional amplification by type-specific primers (SK54/55 for HTLV-I and SK58/59 for HTLV-II) were probed with SK56 and SK60 for identification of HTLV-I and HTLV-1I, respectively (15) . Similarly, amplifications with GAG 49/51 (sequence positions 1427 to 1448, sense strand; positions 1556 to 1535, antisense strand) and 2G1/2G4 (positions 1424 to 1446, sense strand; positions 1559 to 1538, antisense strand) were followed by type-specific probing using GAG 50 (positions 1489 to 1513) and 2G2 (positions 1490 to 1515) for HTLV-I and HTLV-II, respectively. The annealing temperature for 2G1/ 2G4 primer pair was changed to 60°C. The amplified products were analyzed on a 1.8% agarose gel and confirmed by Southern blot hybridization with 32P-labeled probes. Genomic DNA preparations from MT-2 (HTLV-1), MO of normal control. For the Select-HTLV assay, the cutoff value was calculated by adding 0.1 to the mean optical densities (OD) of negative control sera on respective peptides. Specimens with OD less than the cutoff value were considered nonreactive for antibodies to HTLV types I and IT in both the assays. If the absorbance value was higher than the cutoff value in either the HTLV-I or the HTLV-TI peptide assay, the specimen was considered HTLV-I/II positive. The serologic discrimination of HTLV-I/II was based upon the following calculations.
For the SynthEIA assay, the calculated value of HTLV-Ior HTLV-1I-positive specimens was divided by the cutoff value. discriminate between HTLV-I and HTLV-II, the absorbance exceeded the cutoff value in both tests, but the HTLV-grand ratio was between 0.5 and 2.0.
b Nontypeable. In both of the specimens in which the Select-HTLV test failed to discriminate between the two viruses, the OD exceeded the cutoff value in both tests, but the binding ratio was between 0.5 and 2.0 (see "Interpretation of results" and Results).
For the Select-HTLV assay, the binding ratio of each sample is determined by dividing A450 HTLV-II well by A450 HTLV-I well. Binding ratios of -2 and c0.5 signify antibodies to HTLV-II and HTLV-I, respectively. If the binding ratio of a specimen is <2.0 and >0.5, then the sample cannot be distinguished as HTLV-I or HTLV-II.
Nucleotide sequence accession numbers. Sequences for GAG 49/51 and 2G1/2G4 are in GenBank under accession numbers J02029 and M10060, respectively.
RESULTS
Synthetic EIAs for PCR-confirmed seropositive individuals. Among the HTLV-I-infected individuals, serum specimens from 8 of 8 (100%) symptomatic and 21 of 24 (88%) asymptomatic individuals were categorized as HTLV-I by the SynthEIA assay, for an overall test sensitivity of 91% for this virus. Serologic discrimination between HTLV-I and HTLV-II could not be made for 3 of the 32 persons infected with HTLV-I, because although the absorbance exceeded the cutoff value in both EIAs, the HTLV-grand ratio fell between 0.5 and 2.0 (Table 2 ). In contrast, serum specimens from all 32 HTLV-I-infected persons were categorized as HTLV-I by the Select-HTLV assay, resulting in a test sensitivity of 100% for HTLV-I.
Similarly, while only 50 of 57 serum specimens from HTLV-II-infected individuals were categorized as HTLV-II in the SynthEIA test (sensitivity, 88%), 55 of 57 serum specimens were categorized as HTLV-II by the Select-HTLV test (sensitivity, 96%) ( Table 2) . None of the PCRconfirmed HTLV-I-infected persons were incorrectly classified as HTLV-II, and none of the PCR-confirmed HTLV-IIinfected individuals were incorrectly classified as HTLV-I by either assay. Hence, the specificity of both assays for distinguishing the two viruses in seropositive individuals was 100%.
Assessment of synthetic peptide EIAs in HTLV-I/II-infected individuals. Peptide assays were performed on HTLV-I/IIseropositive individuals from whom cells were not available for PCR analysis ( HTLV-II, the absorbance was lower than the cutoff in both EIAs. In one specimen from an ATL patient from the United States and in another from an asymptomatic Japanese person, the absorbance exceeded the cutoff value in both tests, but the HTLV-grand ratio was between 0.5 and 2.0.
b In the single instance in which the Select-HTLV test failed to discriminate between the two viruses, the OD exceeded the cutoff in both the tests, but the binding ratio was between 0.5 and 2.0. 8) and Japan (n = 21) or asymptomatic carriers from Japan (n = 19) were classified as HTLV-I by the Select-HTLV assay (100%), whereas only 41 of 48 (85%) of these specimens were identified as HTLV-I by the SynthEIA assay. Two symptomatic individuals and 3 of 19 asymptomatic persons from Japan had an OD less than the cutoff value in both peptides in SynthEIA tests; in one ATL patient from the United States and in 1 asymptomatic individual from Japan the absorbance exceeded the cutoff in both tests, but the HTLV-grand ratio was between 0.5 and 2.0. None of the Japanese specimens were classified as HTLV-II by either assay. Of the 13 HTLV-I/Il-seropositive Guaymi Indians from Panama (a population that has previously been shown to be endemic for HTLV-II [9] ), all were classified as HTLV-II by the SynthEIA assay, while only 12 of 13 were classified as HTLV-II by the Select-HTLV assay. None of the specimens from the Guaymi Indians were classified as HTLV-I by either assay.
The OD profile of specimens that could not be categorized by the SynthEIA assay in parallel to the profile on Select-HTLV assay (Fig. 1) was evaluated next. Although the Select-HTLV assay had a relatively low OD for HTLV-TI in serum specimens obtained from HTLV-I-infected persons and vice versa, the SynthEIA assay had OD that were comparatively closer to each other in both HTLV-I and HTLV-II assays, suggesting that the epitope recognized by the SynthEIA assays may have some degree of structural homology.
DISCUSSION
With the emergence of HTLV-II as a retrovirus equally as prevalent as HTLV-I among the U.S. blood donor population (3, 27) and the difference in disease association with the two viruses (2), more specific serologic assays are needed to reliably categorize HTLV-I/II-seropositive persons. The ability to accurately distinguish the two viruses would be helpful in conducting seroepidemiologic studies and providing appropriate counseling to persons who test positive for HTLV-I/II. In particular, information regarding HTLV-I- Synthetic peptide-based immunoassays provide us with a tool to begin to look into HTLV-I-and HTLV-II-specific antibody responsiveness.
The HTLV viral genome consists of four major regions, gag, pol, env, and tax. Individuals infected with HTLV usually develop antibodies to gag and env proteins (8) . The envelope proteins of HTLV-I and HTLV-II share the same amino acids at 336 of 488 positions, and 68 of the 152 differences represent conservative changes; 84 amino acids (17%) in the envelope proteins of HTLV-I and HTLV-II are different. Similarly, for the gag protein, 321 of the 429 positions are conserved, 44 have conservative changes, and another 64 (15%) have different compositions in HTLV-I and HTLV-II. On the basis of these considerations, the two proteins ought to have common-sequence-specific and typespecific epitopes.
The synthetic peptides utilized in the assays in this study were derived from the corresponding env gp46 region of HTLV-I and HTLV-II for the SynthEIA assay. The Select-HTLV assay has utilized both env and gag epitopes: a peptide named BCH 234 (29 amino acids) is derived from the p19 protein of HTLV-I, whereas peptide BCH 219 (22 amino acids) is derived from the gp52 glycoprotein of HTLV-II. The C termini of both p19 gag (14, 19, 23) and gp46 env (10, 20, 22, 26) have previously been shown to contain immunodominant epitopes. In the absence of exact sequences, it is difficult to speculate whether these represent similar or different epitopes.
Our study shows that the use of two synthetic peptides derived from HTLV-I and HTLV-II provides an excellent diagnostic tool for type-specific HTLV serologic testing. Both test systems investigated in the present study make use of the relative intensity of antibody response to a given epitope and their respective ratios within a sample (described in Materials and Methods). By using these criteria, we successfully distinguished all 32 serum specimens from HTLV-I-infected persons and 55 of 57 (96%) specimens from HTLV-II-infected persons by the Select-HTLV assay. The SynthEIA test correctly identified 29 of 32 (91%) HTLV-Iinfected serum specimens and 50 of 57 (88%) HTLV-IIinfected serum specimens. More important, neither of the assays categorized an HTLV-I specimen as HTLV-Il or vice versa. The overall sensitivity and specificity of the Select-HTLV assay for detecting HTLV-I (100%, 100%) and HTLV-II (96%, 100%) and the sensitivity and specificity of the SynthEIA assay for HTLV-I (91%, 100%) and HTLV-II (88%, 100%) indicate that these tests can serologically distinguish between HTLV-I and HTLV-II. Serologic discrimination between HTLV-I and HTLV-II has been achieved by a specific Western blotting pattern (28) ; however, recent studies have indicated that such an algorithm has a potential to misclassify a specimen (18) and thus should not be solely relied upon for donor counseling. Because of the 100% specificity of peptide assays, they could reliably be used to type the infection in most HTLV-I/II-positive donors.
The inability of the SynthEIA assay to identify all the specimens as HTLV-I or HTLV-II might be attributed to the secondary structure characteristics of the envelope protein.
Thus, even though a peptide was chosen from a region that has considerable differences between the amino acid sequences of HTLV-I and HTLV-II, the epitope evidently is mimicked in such a way that it is recognized by antibodies in both HTLV-I-and HTLV-Il-infected serum specimens (Fig.  1) . Use of a peptide from the gag gene product (Select-HTLV) clearly eliminated such cross-reacting antibodies, hence increasing the test sensitivity. (pre- sumed to be HTLV-I positive), seropositive persons from Japan (endemic for HTLV-I) and for Guaymi Indians from Panama (endemic for HTLV-II), whose infections could not be categorized because of unavailability of peripheral blood mononuclear cells, showed that specimens obtained from the United States and Japan (from both symptomatic and asymptomatic patients) reacted with HTLV-I in both the Select-HTLV assay and the SynthEIA assay. Of the Guaymi Indian population from Panama, all 13 patients were classified as HTLV-II positive by the SynthEIA assay, while 12 of 13 were classified as HTLV-II positive by the Select-HTLV assay. Thus both assays yielded results consistent with our knowledge of the specific viruses endemic in these populations. We have recently shown that the synthetic peptide assays were also capable of correctly identifying HTLV-I in serum specimens from Papua, New Guinea, and the Solomon Islands (30) .
The use of synthetic peptide-based assays for type-specific serologic testing has several benefits. First, these chemically synthesized epitopes can be manipulated to include typespecific epitopes and therefore yield better specificity for the serologic discrimination between HTLV-I and HTLV-II. Second, the sensitivity of the peptide assays could further be increased by the inclusion of peptides representing additional immunodominant epitopes from the HTLV genome. Such cocktail peptide assays have recently been shown to be highly sensitive and specific for the detection of corresponding HTLV infection (10) .
